ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!CYTO Company Profile and Key Details
Altamira Therapeutics Ltd.
CYTO Stock Price Chart
Stock Price Today
Altamira Therapeutics Ltd. (CYTO) stock remained unchanged at $0.30 a share on NASDAQ. The stock opened at $0.42, fluctuating between $0.30 to $0.42 during the session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Company Information
| Employees | 10 |
| Beta | 2.44 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Altamira Therapeutics Ltd. (NASDAQ: CYTO) stock price is $0.30 in the last trading session. During the trading session, CYTO stock reached the peak price of $0.42 while $0.30 was the lowest point it dropped to. The percentage change in CYTO stock occurred in the recent session was 0% while the dollar amount for the price change in CYTO stock was -.
The NASDAQ listed CYTO is part of Biotechnology industry that operates in the broader Healthcare sector. Altamira Therapeutics Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Marcel Gremaud CPA
Chief Financial Officer
Dr. Covadonga Paneda
Chief Operating Officer
Dr. Thomas Meyer Ph.D.
Founder, Chairman, Chief Executive Officer & MD
Dr. Samuel A. Wickline M.D.
Chief Scientific Adviser
Mr. Marcel Gremaud C.P.A.
Chief Financial Officer
Mr. Jean Lechance
Unit Head of OTC Consumer Health Bus.
Dr. Covadonga Pañeda
Chief Devel. Officer
CYTO's closing price is 328.57% higher than its 52-week low of $0.07 where as its distance from 52-week high of $3.49 is -91.4%.
Number of CYTO employees currently stands at 10.
Official Website of CYTO is: https://altamiratherapeutics.com
CYTO could be contacted at phone 441 295 5950 and can also be accessed through its website. CYTO operates from Clarendon House, Hamilton, HM 11, Bermuda.
CYTO stock volume for the day was 724.3K shares. The average number of CYTO shares traded daily for last 3 months was 141.05K.
The market value of CYTO currently stands at $1.13M with its latest stock price at $0.30 and 3.78M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com